Tecon Biology reports strong mid-year earnings, subsidiary listing progresses

Tecon Biology Co., Ltd. announced a robust financial performance for the first half of 2025, with operating revenue reaching 8.85 bn yuan, a 10.68% increase year-over-year. Net profit attributable to shareholders rose by 22.27% to 338.29 m yuan, while net cash flow from operating activities surged by 109.36% to 1.62 bn yuan. This growth was primarily driven by increases in corn storage and protein and oil processing income.

A significant development is the progress in its subsidiary, Tecon Pharmaceutical Co., Ltd.'s, application to list on the Beijing Stock Exchange. The application was officially accepted on June 23, 2025. Concurrently, Tecon Biology's board approved the termination of a 2020 non-public offering project, reallocating its remaining 50.24 m yuan of raised funds for permanent supplementary working capital.

These strategic shifts in capital deployment, along with strong operational improvements, underscore Tecon Biology’s commitment to optimizing its asset structure and enhancing shareholder value through sustained growth and strategic initiatives. The company plans no cash dividends, bonus shares, or capital reserve conversions for the half-year.